Annual General Meeting of BioNTech SE

17 May 2024

English Convenience Translation: German is the official language.

Slide 1: Annual General Meeting of BioNTech SE

Slide 2: Report of the Management Board on Agenda Item 1

Prof Dr Ugur Sahin, CEO & Co-Founder

[Slide 3: Operational development 2023 & Q1 2024 and Outlook 2024]

Ladies and Gentlemen, shareholders, and shareholder representatives.

On behalf of my colleagues on the Management Board, I would like to welcome you to the Annual General Meeting of BioNTech.

[Slide 4: This Slide Presentation Includes Forward-Looking Statements]

Before we begin our report, please be advised that we will be making “forward-looking statements” in this Annual General Meeting.

As described on this slide of the presentation, these statements are subject to the risks and uncertainties detailed in our filings with the U.S. SEC, including our most recent Annual Report on Form 20-F. These statements, including, without limitation, those relating to our COVID-19 vaccine revenues, as these include figures that are derived from preliminary estimates provided by our partners; our estimated financial results for 2024; the continued global demand for our COVID-19 vaccine; and the planned next steps in our pipeline programs.

Actual results may differ materially from those projected in these statements. All information in this presentation is current as of the date of its preparation and BioNTech assumes no obligation to update such information.

[Slide 5: Our Vision]

I would like to take the opportunity of today's Annual General Meeting to thank all BioNTech employees and collaboration partners for their passionate and successful work in 2023 and this year. I would also like to thank the patients and the physicians treating them. It is their contribution that enables us to work together to improve the standard of medical care.

2023 was a year in which we made important progress in many areas: We maintained our position in the COVID-19 vaccine market. We advanced our oncology pipeline, publishing encouraging data for product candidates from our oncology pipeline and initiating potentially registrational trials. We have also strengthened our organization in preparation for the next phase of growth, particularly in view of our planned market launches in oncology.

Here at BioNTech, we have a unique opportunity to create added value for patients, society, and investors.

[Slide 6: Our Vision: Harnessing the Power of the Immune System to Fight Human Disease]

The successful development of our COVID-19 vaccine during the pandemic accelerated our mission, but our vision remains unchanged: We aim to harness the power of the immune system to fight cancer and other serious diseases.

The following objectives are linked to this:

1. We want to develop BioNTech into a globally leading, sustainable and successful biotechnology company. A company with a broad range of approved products that address global medical needs.
2. In oncology, in particular, we aim to obtain several product approvals for innovative precision medicines in the coming years.
3. In addition to this, we are building a sustainable respiratory vaccine business, with our COVID-19 vaccine franchise playing an integral role.

[Slide 7: Diversified Oncology Pipeline]

The years 2020 to 2022 were characterized by the development, large-scale production, and commercialization of our COVID-19 vaccine together with Pfizer. 2023 was a year in which we refocused on the development of our oncology pipeline. We further expanded our strategy, adding advanced product candidates in additional drug classes to our pipeline. We believe that our novel therapies could complement or replace established cancer treatments in many areas in the future.

[Slide 8: Root Cause of Cancer Treatment Failure]

I would like to begin by briefly addressing one of the fundamental challenges in cancer treatment. This is the reason why many established therapeutic approaches are only effective for a limited period of time, especially if the disease is not detected at an early stage.

Cancer is a highly individualized disease caused by successive changes in the genetic material of healthy cells. These genetic changes, called mutations, are random and vary in number from patient to patient. Even the cancer cells within a tumor are different, so that after an apparently successful therapy in which most of the tumor cells have been destroyed, resistant cancer cells remain which can divide and multiply again.

In such cases, the cancer comes back after a few months or years and is then sometimes so aggressive that it can no longer be controlled.

This is the scientific background against which we aim to improve the standard of treatment for patients. Our medicines are divided into three different therapeutic approaches, which I would like to discuss in more detail in the next slide.

[Slide 9: Towards a Potentially Curative Approach to Cancer: Differentiated Combinations]

Our long-term strategy in the field of oncology is aimed at expanding treatment options for cancer patients. We are committed to meeting the needs of cancer patients across the entire continuum of cancer - from adjuvant therapies, i.e., therapies that aim to prevent the cancer

from recurring after surgical removal of a tumor, to treatment options for patients with late-stage, inoperable cancers.

Based on our decades of research experience in the field of immunological therapies, we have built up a portfolio of compound classes that may have synergistic mechanisms of action. It comprises three distinct categories:

- First, we are developing candidates for targeted therapies, including CAR-T cell therapies and chemotherapy-targeted antibodies, or ADCs. CAR-T cells are the patient's own immune cells that have been engineered to specifically recognize the surface features of target cells. ADCs are therapeutic antibodies that also specifically recognize the surface characteristics of cells and then deliver toxic substances into these target cells. Both target the cancer cells directly and are designed to suppress advanced cancer.
- Second, we are developing therapies that boost the immune system itself. This may be particularly effective in cancers where the cancer suppresses immune responses directed against itself and thus escapes effective immune control.
- The third class of candidates is personalized mRNA cancer vaccines. This is an area in which we are a global leader in research and development. These personalized mRNA cancer vaccine candidates are specifically tailored to the cancer of the respective patient.

  We have demonstrated in several clinical trials that therapeutic cancer vaccines induce long-lasting immune responses of the patient's immune system against cancer cells. After vaccination, the immune cells are able to recognize different features on cancer cells, known as antigens. This enables them to overcome the heterogeneity of cancer cells, potentially eliminating metastatic cancers to achieve a lasting effect.

We are one of the few companies researching such a diverse toolbox with different mechanisms of action - including whether and how these could be combined and act synergistically to enhance their effects. Our strategy is to first clinically prove the efficacy and

tolerability of our individual product candidates, then advance suitable candidates to registrational trials and, in parallel, explore potential synergies in combination therapy trials.

[Slide 10: Investing Through Waves of Innovation with the Aim to Transform Cancer Treatment]

Some of our product candidates are already in mid- to late-stage clinical development. Our aim is to drive the clinical development of these product candidates towards approval. By the end of 2024, we aim to start ten or more potentially registrational trials across multiple indications. If successful, we aim to launch the first product in 2026 and to achieve ten oncology indication approvals by 2030.

We want to develop BioNTech into a company that creates added value for patients, society, and investors by securing marketing authorizations in a variety of indications.

[Slide 11: Sustainable pipeline for COVID-19 and Infectious Disease]

Let us now turn to our commercialized COVID-19 vaccine Comirnaty and our infectious disease pipeline.

[Slide 12: We Made History]

When the COVID-19 pandemic broke out, we rose to the challenge of making life-saving vaccines available worldwide. According to the journal Nature, the development of Comirnaty was the "fastest vaccine development in the history of medicine" and, to date, we have delivered over 4.8 billion doses to more than 180 countries.

COVID-19 vaccines were introduced in Europe in December 2020. Since then, the number of COVID-19 deaths in the WHO Europe region has fallen by around 57%, according to World Health Organization statistics. Safe and effective COVID-19 vaccines have saved at least 1.4 million lives in Europe. Our COVID-19 vaccine has made a significant contribution to this and we are very proud of this achievement.

This success underlines not only the versatility of our mRNA technology, but also our ability as a company to translate research into innovation and deliver results.

[Slide 13: Long-Term Need for Annually Adapted Vaccines Anticipated]

By leveraging our innovative capabilities and Pfizer's global infrastructure, we aim to maintain and expand our leadership in the fight against COVID-19.

Developments in the incidence of infection in 2023 will allow us to better assess the future need for COVID-19 vaccines, as there has been a transition from a pandemic situation to an endemic-like situation, with an increase in infections during the colder months.

We know that vaccine protection against SARS-CoV-2 infection, whether acquired by vaccination or naturally following infection, wanes over time. We therefore expect COVID-19 to remain an annual seasonal infectious disease, with most cases occurring during the typical flu and cold season.

Data from the 2023-2024 autumn-winter season show that COVID-19 will remain a significant health risk even after the pandemic:

- In Germany, for example, most of the officially reported infections last season were due to SARS-CoV-2, which was associated with more hospitalizations and deaths than influenza.
- The World Health Organization and the German Robert Koch Institute estimate that 10 to 20% of people infected with SARS-CoV-2 go on to develop Long COVID.

Vaccination will therefore remain an important component in the prevention of illnesses and severe disease in autumn/winter, similar to the influenza vaccination.

[Slide 14: COVID-19 Franchise: Adaptable Approach in the Face of Dynamic Virus Evolution for Continued Success]

Our goal is to provide people around the world with COVID-19 vaccines that are adapted to newly circulating virus variants or sub-lineages. We therefore developed and commercialized

a seasonally adapted monovalent COVID-19 vaccine for the 2023/2024 season. In response to demand, we have launched single-dose vials and non-frozen prefilled syringes in the U.S. In addition, we aim to improve the product characteristics of our COVID-19 vaccine Comirnaty, for example, by extending its half-life and increasing immunogenicity.

We are currently developing a new adapted COVID-19 vaccine for the 2024/2025 season and have continued to work with Pfizer on combination vaccine candidates. We initiated a Phase 3 clinical trial for our joint COVID-19 and influenza vaccine candidate in December 2023. In this way, we aim to build a sustainable respiratory vaccine business and maintain a market-leading position in COVID-19 vaccines.

[Slide 15: Infectious Diseases: Important Clinical Development Area Addressing High Medical and Global Health Need]

I would now like to outline our infectious disease research programs.

In addition to the clinical development of vaccines against COVID-19 and influenza, we are focusing on the development of prophylactic mRNA vaccines against infectious diseases such as tuberculosis and malaria, against latent viruses such as herpes simplex and varicella zoster and diseases with epidemic and pandemic risk such as Mpox.

We focus on diseases that represent both high unmet medical need and a global health burden: Together, they claim millions of lives worldwide every year and there are no adequate treatments or vaccines available.

We believe our innovative vaccines could successfully address these challenges.

[Slide 16: Execution in 2023]

We have achieved a lot in 2023 and in the first quarter of 2024.

I would now like to talk about our achievements and goals.

[Slide 17: Developing an Innovative Pipeline Focused on Oncology and Infectious Disease]

We have continued to develop our innovative pipeline with a focus on oncology and infectious diseases. The pipeline currently comprises more than 20 ongoing clinical programs in oncology and seven in infectious diseases, which are being investigated in more than 35 clinical trials. In oncology, we now have several potentially registrational trials ongoing. We started nine clinical trials in 2023 and the first quarter of 2024 and in-licensed six new clinical drug candidates.

In the area of infectious diseases, we have initiated three first-in-human phase 1 clinical trials with our proprietary mRNA prophylaxis vaccine technology, including candidates being tested against shingles, tuberculosis and Mpox.

Over the course of 2024, we aim to advance further product candidates into late-stage development. We expect to have at least ten registrational trials underway by the end of the year.

[Slide 18: Corporate Execution in 2023 and Q1 2024]

In 2023 and early 2024, we entered into new collaborations to strengthen our core technologies and gain access to complementary technologies.

Since BioNTech's foundation, our focus has been on increasing the use of data science, AI and machine learning.

With the acquisition of InstaDeep, we have integrated expertise in the areas of supercomputing, AI-based research and generative AI into our processes. Our goal is to

- Increase the probability of success of our clinical research programs.
- Identify and optimize new innovative molecules and combinations of molecules.
- And improve and accelerate workflows.

We also expanded our technology base in the area of targeted therapies by in-licensing new antibody drug conjugates (ADCs) through our collaborations with DualityBio and MediLink Therapeutics. We believe that ADCs could replace highly toxic chemotherapies as a new pillar of combination cancer therapy.

Other collaborations announced in 2023 with the companies OncoC4 and Biotheus have added more next-generation antibodies to our pipeline. Two candidates from these collaborations - BNT316 and BNT323 – entered registrational trials within six months of signing the agreement.

In 2024, we started a strategic collaboration with Autolus, a CAR-T cell therapy company. This collaboration aims to advance the development of both companies' CAR-T programs towards commercialization. This alliance will allow us to leverage Autolus' manufacturing and distribution infrastructure and expand the development of our lead CAR-T cell therapy program, BNT211, into clinical trials in multiple tumor indications.

These collaborations show that we are leveraging our strong financial position to continously invest in research and development.

With this strong financial position, our leading COVID-19 vaccine franchise and an innovative pipeline in oncology and infectious diseases, we are well positioned to realize our vision of becoming a multi-product company through organic innovation as well as strategic acquisitions, collaborations and partnerships.

[Slide 19: BioNTech Today]

On the next slide, I would like to give you a brief factual overview of the company´s expansion: We have built a diverse team of over 6,300 people from different disciplines and nationalities to deliver on our strategic priorities. More than half of our employees are women.

In 2023, we have initiated several partnerships and one acquisition. These are designed to support the development of immunotherapies and vaccines as well as broadening access to our product candidates. In this way, we can ensure that the progress made with our vaccine and product development reaches people around the world as quickly as possible.

Our milestones in the area of internationalization for 2023 include:

- Integration of our InstaDeep colleagues into our organization and processes, whereby InstaDeep has remained an independent entity headquartered in London.
- Inauguration of our new facility in Rwanda, which is expected to be the first commercial mRNA production facility on the African continent. I will go into this in more detail shortly.

- A multi-year partnership to strengthen the mRNA ecosystem in the Australian state of Victoria, under which BioNTech will establish and operate a clinical-scale mRNA production facility.
- Finally, our GMP manufacturing facility in Singapore is nearing completion. This site is an important pillar for our growing pipeline of mRNA-based therapeutics in the Asia-Pacific region, both clinically and commercially.

[Slide 20: Accelerate and Enhance BioNTech's AI Vision]

BioNTech is committed to harnessing the power of digitalization and automation to further improve the health of people worldwide.Last year we announced the successful completion of the acquisition of InstaDeep. In addition to world-class artificial intelligence and machine learning technologies, we gained research capabilities that will drive and strengthen our strategic vision.

The acquisition added around 300 data scientists, machine learning engineers and technical experts to our organization. We have positioned ourselves as a leader in this highly innovative field. By combining InstaDeep's AI and machine learning expertise with our own research and development capabilities, we aim to develop novel therapeutic products and vaccines faster and more efficiently. Examples include the optimization of mRNA and protein design, and the end-to-end optimization of personalized medicines from genome and mutanome analysis, to target selection and manufacturing.

We want to utilize AI not only in research and development, but in all areas of the company and improve our processes and performance. This makes it a highly strategic acquisition with significant long-term transformational potential for our entire business.

[Slide 21: Healthcare and Social Responsibility]

I would now like to address the subject of social responsibility. At BioNTech, we are committed to contributing to healthcare and to fulfilling our social and corporate responsibility. Our global strategy and our day-to-day activities are focused on improving the health of as many people as possible through our innovations. As a company, we are therefore focused on contributing to more equitable access to new medicines worldwide.

One example of this is our manufacturing facility in Kigali, Rwanda, which was inaugurated in December 2023 and is expected to be the first mRNA manufacturing facility in Africa. This facility houses our BioNTainer units. BioNTainer is a flexible container solution for a turnkey manufacturing facility for local, scalable mRNA vaccine production. BioNTainer units are designed to ensure sustainable, equitable access to new medicines - particularly in regions with limited infrastructure.

We plan to complete all production buildings at the Kigali site this year. mRNA test production for process validation is scheduled to start in 2025.

A Global Health Office has been established within the company. Its mission is to support the development of innovative medicines for diseases with high unmet medical need, such as malaria, tuberculosis or HIV, particularly in low- and middle-income countries.

In addition, more than 30% of the COVID-19 vaccines we produced were delivered to low- and middle-income countries in 2023, in line with demand. This is our contribution to fair and equitable access to innovative treatments.

[Slide 22: Outlook 2024]

Let me conclude by summarizing our key strategic goals for 2024.

[Slide 23: Strategic Vision for 2030]

The development of the COVID-19 vaccine transformed BioNTech. Achieving our goals for our oncology pipeline has the potential to do the same. We believe that we are well positioned to capitalize on this opportunity. Our Strategy 2030 aims to further develop BioNTech into a diversified, cash-generating, multi-product company with sustainable, long-term growth by 2030.

Together with our partner Pfizer, we plan to further strengthen and expand our leadership in COVID-19 vaccines. This will be based on the ongoing development of our vaccine candidates, the development of combination vaccines and the continuous improvement of the product properties of our COVID-19 vaccine.

2024 will also be an important year in achieving our commercialization goals for our oncology portfolio. This year will focus on building our commercial organization and progressing product development, particularly into potentially registrational trials. Our goal is to selectively expand and advance our oncology pipeline, select the best product candidates and advance potentially registrational clinical trials. In the next 18 months, we are planning to present data for several of our product candidates. We aim for our first oncology approval in 2026. We are targeting ten indication approvals by 2030.

We also plan to further advance and expand our infectious disease pipeline in 2024. With seven programs in early clinical development today, our long-term focus until 2030 is to bring the vaccines to market and build a pipeline of late-stage products outside of our respiratory vaccine business.

For BioNTech, 2024 represents a new beginning. As part of this great team, I look forward to bringing our product candidates closer to market approval and demonstrating the value we add to society. We have the opportunity to drive change in medicine. I believe we have everything it takes to establish BioNTech as one of the leading global immunotherapy companies.

Our vision is made possible by the unrivalled commitment, passion and hard work of our employees. We would like to thank you, our valued shareholders, for your continued confidence, patience and support over the past few years. It gives us confidence as we take the next steps together in executing our strategy and realizing our vision.

Thank you for your attention. I will now hand the meeting back to our Meeting Chairman.